- enrolling by invitationPHASE1, PHASE2
Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis
This study compares a new nasal powder (FMXIN002) to the EpiPen for treating severe allergic reactions. We're testing how the body handles the new medicine and how well it works in healthy adults with hay fever, checking different doses and nasal conditions.
Canada - recruiting
EPAP, Interviewstudy
Researchers are studying why some people with food allergies have repeated severe reactions (anaphylaxis). They want to understand if certain foods are more likely to cause this, and how people manage their allergies. Participants will answer surveys online for two years to help improve care for future patients.
Germany - enrolling by invitation
The Alberta BLOOM Premature Child Study
This study looks at how tiny living things (microbes) in premature babies' guts develop. It aims to understand how these microbes might affect their risk of developing allergies and asthma as they grow up, and what factors influence this development.
Canada - recruiting
Direct Oral Challenges in Private Practice Setting to Delabeling Children With Beta-lactam Allergy
This study looks at whether it's safe and practical for children to have a special test, called an oral challenge, done at a private doctor's office. This test helps find out if a child truly has a mild, delayed allergy to certain antibiotics called beta-lactams, rather than just assuming they do.
France - ongoing, recruitingTherapeutic use (Phase IV)
A single-centre, randomized, double blind, placebo controlled, crossover, single dose clinical trial to compare orodispersible presentations of bilastine, ebastine, and desloratadine in the suppression of wheal and flare induced by intradermal histamine in healthy volunteers.
This study looks at how quickly different allergy medications in a fast-dissolving form start to work. Researchers will give healthy volunteers a small amount of an irritating substance on their skin and then see how well the medications reduce the resulting redness and swelling compared to a dummy pill.
Spain - active not recruitingPHASE3
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
This study is looking at the safety of a new patch treatment, called Viaskin Peanut Patch (DBV712), for peanut allergy in very young children (1 to 3 years old). It aims to see if the patch is safe over six months, with some children receiving the patch and others a dummy patch.
United States · Australia · Canada